개 아토피 피부염 시장 규모, 점유율, 동향 분석 보고서 : 제품 유형별, 견종별, 투여 방법별, 적응증별, 유통 채널별, 지역별 및 부문 동향(2025-2030년)

Canine Atopic Dermatitis Market Growth & Trends:

The global canine atopic dermatitis market size is anticipated to reach USD 8.78 billion by 2030 and expand at a CAGR of 10.6% during the forecast period, according to a new report by Grand View Research, Inc. The rising prevalence of canine atopic dermatitis and advancements in veterinary medicine are driving market growth. Increasing cases of skin allergies in dogs have led to higher demand for effective treatments. Innovations such as monoclonal antibodies and improved immunosuppressants enhance therapeutic outcomes, fueling market expansion. Research and development efforts continue to drive novel therapies, improving treatment efficacy and accessibility.

Growing pet ownership and increased awareness among pet owners propel the canine atopic dermatitis market. As more households adopt dogs, the demand for dermatological care rises. Pet owners are becoming more proactive in seeking treatment, leading to higher adoption of specialized therapies. The rise in pet healthcare spending and improved diagnostic capabilities further contribute to market growth.

The increasing focus on companion animal wellness and expanding veterinary healthcare infrastructure are expected to drive market growth. Enhanced veterinary facilities and specialized dermatology clinics improve access to advanced treatments. Rising investments in pet healthcare further support the market expansion, with pharmaceutical companies developing innovative solutions to meet growing demand.

Canine Atopic Dermatitis Market Report Highlights:

• By product, the glucocorticoids segment led the market with the largest revenue share of 38.3% in 2024, fueled by its widespread use in managing inflammation and allergic reactions in dogs.
• The MAbs segment is set to be the fastest-growing segment during the forecast period,attributed to its targeted approach to managing allergic reactions.
• By type, the prescription segment dominated the market with the largest share in 2024, driven by the growing reliance on veterinarian-recommended treatments.
• The OTC segment is set to witness the fastest growth from 2025 to 2030 due to increasing preference for accessible and affordable treatments.
• North America accounted for the largest revenue share of 40.4% in 2024, propelled by its advanced veterinary healthcare infrastructure and high pet ownership rates.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Type
  • 1.2.3. Dog Breed
  • 1.2.4. Mode of Administration
  • 1.2.5. Indication
  • 1.2.6. Distribution Channel
  • 1.2.7. Regional Scope
  • 1.2.8. Estimates and Forecasts Timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
  • 1.4.3. Secondary Sources
  • 1.4.4. Primary Research
  • 1.4.5. Details of Primary Research
• 1.5. Information or Data Analysis
  • 1.5.1. Data Analysis Models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product Outlook
  • 2.2.2. Type Outlook
  • 2.2.3. Dog Breed Outlook
  • 2.2.4. Mode of Administration Outlook
  • 2.2.5. Indication Outlook
  • 2.2.6. Distribution Channel Outlook
  • 2.2.7. Regional Outlook
• 2.3. Competitive Scenario

Chapter 3. Canine Atopic Dermatitis Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Canine Atopic Dermatitis Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrant
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis
    • 3.3.2.1. Political Landscape
    • 3.3.2.2. Technological Landscape
    • 3.3.2.3. Economic Landscape

Chapter 4. Canine Atopic Dermatitis Market: Product Estimates & Trend Analysis

• 4.1. Product Segment Dashboard
• 4.2. Canine Atopic Dermatitis Market: Product Movement Analysis
• 4.3. Global Canine Atopic Dermatitis Market Size & Trend Analysis, By Product, 2018 to 2030 (USD Million)
• 4.4. Glucocorticoids
  • 4.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 4.5. Antihistamines
  • 4.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 4.6. Immunosuppressants
  • 4.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 4.7. MAbs
  • 4.7.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 4.8. Others
  • 4.8.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 5. Canine Atopic Dermatitis Market: Type Estimates & Trend Analysis

• 5.1. Type Segment Dashboard
• 5.2. Canine Atopic Dermatitis Market: Type Movement Analysis
• 5.3. Global Canine Atopic Dermatitis Market Size & Trend Analysis, By Type, 2018 to 2030 (USD Million)
• 5.4. Prescription
  • 5.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 5.5. OTC
  • 5.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 6. Canine Atopic Dermatitis Market: Dog Breed Estimates & Trend Analysis

• 6.1. Dog Breed Segment Dashboard
• 6.2. Canine Atopic Dermatitis Market: Dog Breed Movement Analysis
• 6.3. Global Canine Atopic Dermatitis Market Size & Trend Analysis, By Dog Breed, 2018 to 2030 (USD Million)
• 6.4. German Shepherd
  • 6.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 6.5. Terriers
  • 6.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 6.6. Retrievers
  • 6.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 6.7. Others
  • 6.7.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 7. Canine Atopic Dermatitis Market: Mode of Administration Estimates & Trend Analysis

• 7.1. Mode of Administration Segment Dashboard
• 7.2. Canine Atopic Dermatitis Market: Mode of Administration Movement Analysis
• 7.3. Global Canine Atopic Dermatitis Market Size & Trend Analysis, By Mode of Administration, 2018 to 2030 (USD Million)
• 7.4. Oral
  • 7.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 7.5. Topical
  • 7.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 7.6. Injectable
  • 7.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 8. Canine Atopic Dermatitis Market: Indication Estimates & Trend Analysis

• 8.1. Indication Segment Dashboard
• 8.2. Canine Atopic Dermatitis Market: Indication Movement Analysis
• 8.3. Global Canine Atopic Dermatitis Market Size & Trend Analysis, By Indication, 2018 to 2030 (USD Million)
• 8.4. Ectoparasites
  • 8.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 8.5. Food Allergy
  • 8.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 8.6. Allergic Skin Infections
  • 8.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 8.7. Others
  • 8.7.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 9. Canine Atopic Dermatitis Market: Distribution Channel Estimates & Trend Analysis

• 9.1. Distribution Channel Segment Dashboard
• 9.2. Canine Atopic Dermatitis Market: Distribution Channel Movement Analysis
• 9.3. Global Canine Atopic Dermatitis Market Size & Trend Analysis, By Distribution Channel, 2018 to 2030 (USD Million)
• 9.4. Veterinary Hospitals/Clinics
  • 9.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 9.5. Retail
  • 9.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 9.6. E-commerce
  • 9.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 10. Canine Atopic Dermatitis Market: Regional Estimates & Trend Analysis

• 10.1. Regional Market Dashboard
• 10.2. Regional Market Share Analysis, 2024 & 2030
• 10.3. Canine Atopic Dermatitis Market by Region: Key Takeaways
• 10.4. North America
  • 10.4.1. U.S.
    • 10.4.1.1. Key Country Dynamics
    • 10.4.1.2. Regulatory Framework/ Reimbursement Structure
    • 10.4.1.3. Competitive Scenario
    • 10.4.1.4. U.S. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 10.4.2. Canada
    • 10.4.2.1. Key Country Dynamics
    • 10.4.2.2. Regulatory Framework/ Reimbursement Structure
    • 10.4.2.3. Competitive Scenario
    • 10.4.2.4. Canada Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 10.4.3. Mexico
    • 10.4.3.1. Key Country Dynamics
    • 10.4.3.2. Regulatory Framework/ Reimbursement Structure
    • 10.4.3.3. Competitive Scenario
    • 10.4.3.4. Mexico Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 10.5. Europe
  • 10.5.1. U.K.
    • 10.5.1.1. Key Country Dynamics
    • 10.5.1.2. Regulatory Framework/ Reimbursement Structure
    • 10.5.1.3. Competitive Scenario
    • 10.5.1.4. U.K. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 10.5.2. Germany
    • 10.5.2.1. Key Country Dynamics
    • 10.5.2.2. Regulatory Framework/ Reimbursement Structure
    • 10.5.2.3. Competitive Scenario
    • 10.5.2.4. Germany Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 10.5.3. France
    • 10.5.3.1. Key Country Dynamics
    • 10.5.3.2. Regulatory Framework/ Reimbursement Structure
    • 10.5.3.3. Competitive Scenario
    • 10.5.3.4. France Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 10.5.4. Italy
    • 10.5.4.1. Key Country Dynamics
    • 10.5.4.2. Regulatory Framework/ Reimbursement Structure
    • 10.5.4.3. Competitive Scenario
    • 10.5.4.4. Italy Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 10.5.5. Spain
    • 10.5.5.1. Key Country Dynamics
    • 10.5.5.2. Regulatory Framework/ Reimbursement Structure
    • 10.5.5.3. Competitive Scenario
    • 10.5.5.4. Spain Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 10.5.6. Denmark
    • 10.5.6.1. Key Country Dynamics
    • 10.5.6.2. Regulatory Framework/ Reimbursement Structure
    • 10.5.6.3. Competitive Scenario
    • 10.5.6.4. Denmark Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 10.5.7. Sweden
    • 10.5.7.1. Key Country Dynamics
    • 10.5.7.2. Regulatory Framework/ Reimbursement Structure
    • 10.5.7.3. Competitive Scenario
    • 10.5.7.4. Sweden Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 10.5.8. Norway
    • 10.5.8.1. Key Country Dynamics
    • 10.5.8.2. Regulatory Framework/ Reimbursement Structure
    • 10.5.8.3. Competitive Scenario
    • 10.5.8.4. Norway Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 10.6. Asia Pacific
  • 10.6.1. Japan
    • 10.6.1.1. Key Country Dynamics
    • 10.6.1.2. Regulatory Framework/ Reimbursement Structure
    • 10.6.1.3. Competitive Scenario
    • 10.6.1.4. Japan Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 10.6.2. China
    • 10.6.2.1. Key Country Dynamics
    • 10.6.2.2. Regulatory Framework/ Reimbursement Structure
    • 10.6.2.3. Competitive Scenario
    • 10.6.2.4. China Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 10.6.3. India
    • 10.6.3.1. Key Country Dynamics
    • 10.6.3.2. Regulatory Framework/ Reimbursement Structure
    • 10.6.3.3. Competitive Scenario
    • 10.6.3.4. India Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 10.6.4. Australia
    • 10.6.4.1. Key Country Dynamics
    • 10.6.4.2. Regulatory Framework/ Reimbursement Structure
    • 10.6.4.3. Competitive Scenario
    • 10.6.4.4. Australia Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 10.6.5. South Korea
    • 10.6.5.1. Key Country Dynamics
    • 10.6.5.2. Regulatory Framework/ Reimbursement Structure
    • 10.6.5.3. Competitive Scenario
    • 10.6.5.4. South Korea Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 10.6.6. Thailand
    • 10.6.6.1. Key Country Dynamics
    • 10.6.6.2. Regulatory Framework/ Reimbursement Structure
    • 10.6.6.3. Competitive Scenario
    • 10.6.6.4. Thailand Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 10.7. Latin America
  • 10.7.1. Latin America Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 10.7.2. Brazil
    • 10.7.2.1. Key Country Dynamics
    • 10.7.2.2. Regulatory Framework/ Reimbursement Structure
    • 10.7.2.3. Competitive Scenario
    • 10.7.2.4. Brazil Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 10.7.3. Argentina
    • 10.7.3.1. Key Country Dynamics
    • 10.7.3.2. Regulatory Framework/ Reimbursement Structure
    • 10.7.3.3. Competitive Scenario
    • 10.7.3.4. Argentina Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 10.8. Middle East and Africa
  • 10.8.1. Middle East and Africa Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 10.8.2. South Africa
    • 10.8.2.1. Key Country Dynamics
    • 10.8.2.2. Regulatory Framework/ Reimbursement Structure
    • 10.8.2.3. Competitive Scenario
    • 10.8.2.4. South Africa Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 10.8.3. Saudi Arabia
    • 10.8.3.1. Key Country Dynamics
    • 10.8.3.2. Regulatory Framework/ Reimbursement Structure
    • 10.8.3.3. Competitive Scenario
    • 10.8.3.4. Saudi Arabia Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 10.8.4. UAE
    • 10.8.4.1. Key Country Dynamics
    • 10.8.4.2. Regulatory Framework/ Reimbursement Structure
    • 10.8.4.3. Competitive Scenario
    • 10.8.4.4. UAE Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 10.8.5. Kuwait
    • 10.8.5.1. Key Country Dynamics
    • 10.8.5.2. Regulatory Framework/ Reimbursement Structure
    • 10.8.5.3. Competitive Scenario
    • 10.8.5.4. Kuwait Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 11. Competitive Landscape

• 11.1. Recent Developments & Impact Analysis, By Key Market Participants
• 11.2. Company/ Competition Categorization
• 11.3. Vendor Landscape
  • 11.3.1. Key Company Heat Map Analysis, 2024
• 11.4. Company Profiles
  • 11.4.1. Zoetis Services LLC
    • 11.4.1.1. Company Overview
    • 11.4.1.2. Financial Performance
    • 11.4.1.3. Product Benchmarking
    • 11.4.1.4. Strategic Initiatives
  • 11.4.2. Merck & Co., Inc.
    • 11.4.2.1. Company Overview
    • 11.4.2.2. Financial Performance
    • 11.4.2.3. Product Benchmarking
    • 11.4.2.4. Strategic Initiatives
  • 11.4.3. Elanco
    • 11.4.3.1. Company Overview
    • 11.4.3.2. Financial Performance
    • 11.4.3.3. Product Benchmarking
    • 11.4.3.4. Strategic Initiatives
  • 11.4.4. Boehringer Ingelheim International GmbH
    • 11.4.4.1. Company Overview
    • 11.4.4.2. Financial Performance
    • 11.4.4.3. Product Benchmarking
    • 11.4.4.4. Strategic Initiatives
  • 11.4.5. Virbac
    • 11.4.5.1. Company Overview
    • 11.4.5.2. Financial Performance
    • 11.4.5.3. Product Benchmarking
    • 11.4.5.4. Strategic Initiatives
  • 11.4.6. Vetoquinol
    • 11.4.6.1. Company Overview
    • 11.4.6.2. Financial Performance
    • 11.4.6.3. Product Benchmarking
    • 11.4.6.4. Strategic Initiatives
  • 11.4.7. Dechra
    • 11.4.7.1. Company Overview
    • 11.4.7.2. Financial Performance
    • 11.4.7.3. Product Benchmarking
    • 11.4.7.4. Strategic Initiatives
  • 11.4.8. Biofelix Pharma Group
    • 11.4.8.1. Company Overview
    • 11.4.8.2. Financial Performance
    • 11.4.8.3. Product Benchmarking
    • 11.4.8.4. Strategic Initiatives
  • 11.4.9. TORAY INDUSTRIES, INC.
    • 11.4.9.1. Company Overview
    • 11.4.9.2. Financial Performance
    • 11.4.9.3. Product Benchmarking
    • 11.4.9.4. Strategic Initiatives
  • 11.4.10. Bioiberica S.A.U.
    • 11.4.10.1. Company Overview
    • 11.4.10.2. Financial Performance
    • 11.4.10.3. Product Benchmarking
    • 11.4.10.4. Strategic Initiatives
  • 11.4.11. Ceva
    • 11.4.11.1. Company Overview
    • 11.4.11.2. Financial Performance
    • 11.4.11.3. Product Benchmarking
    • 11.4.11.4. Strategic Initiatives
  • 11.4.12. Bimeda, Inc.
    • 11.4.12.1. Company Overview
    • 11.4.12.2. Financial Performance
    • 11.4.12.3. Product Benchmarking
    • 11.4.12.4. Strategic Initiatives